司美格鲁肽治疗儿童肥胖的观察性研究
该回顾性观察研究评估了司美格鲁肽对50例10-18岁伴有合并症的肥胖儿童的疗效与耐受性。治疗6个月后,BMI SDS、体重和体重百分比均显著下降;14例有12个月数据的患者也显示持续显著改善。轻度胃肠道副作用常见,5例因副作用停药。
要点
- 治疗6个月BMI SDS下降0.32±0.27,体重下降7.03±7.50 kg。
- 14例12个月数据:BMI SDS下降0.54±0.52,体重下降9.7±10.8 kg。
- 轻度胃肠道副作用常见,1例出现胆结石,5例因副作用停药。
核心结论
- 司美格鲁肽在多学科体重管理诊所中使用时,似乎是安全有效的减重辅助手段。
研究设计与样本
- 回顾性观察研究,纳入某英国医院三级儿科多学科体重管理诊所的前50例接受司美格鲁肽治疗至少6个月的10-18岁肥胖儿童。
主要发现
- 治疗6个月后,BMI SDS下降0.32±0.27(p<0.001),体重下降7.03±7.50 kg(p<0.001),平均总体重百分比下降6.4±6.3%(p<0.001)。
- 14例有12个月数据的患者中,平均BMI SDS下降0.54±0.52(p<0.001),平均体重下降9.7±10.8 kg(p<0.001),12个月总体重百分比下降8.9±10.0%(p<0.001)。
- 轻度胃肠道副作用常见,1例出现胆结石,5例因副作用停止治疗。
关键数值与推荐
- 纳入标准:年龄10-18岁,BMI SDS>2,且伴有体重相关合并症(包括胰岛素抵抗(定义为HOMA-IR>4)、2型糖尿病、代谢相关脂肪性肝病、阻塞性睡眠呼吸暂停或高血压)。
- 干预方案:每周一次皮下注射司美格鲁肽,8周内滴定至最终剂量1 mg,并辅以饮食和生活方式建议。
临床怎么用
- 在儿科多学科体重管理诊所中,可考虑将司美格鲁肽作为伴有合并症的肥胖儿童减重辅助治疗,但需监测胃肠道副作用和胆结石等不良反应。
局限性
- 本研究为回顾性观察研究,样本量较小(50例),仅14例有12个月数据,缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess efficacy and tolerability of semaglutide as a weight loss treatment for children living with comorbid obesity. DESIGN: Retrospective observational study of the first 50 children from a weight management service treated with semaglutide for at least 6 months. SETTING: A tertiary paediatric multidisciplinary weight management clinic in a UK hospital. PATIENTS: Aged 10-18 years old with a body mass index (BMI) SD score (SDS) >2 with a weight-related comorbidity (including insulin resistance (defined as homeostatic model assessment for insulin resistance >4), type 2 diabetes, metabolic-associated fatty liver disease, obstructive sleep apnoea or hypertension). INTERVENTIONS: Once-weekly injectable semaglutide titrated over 8 weeks to a final dose of 1 mg in addition to dietary and lifestyle advice. MAIN OUTCOME MEASURES: Primary outcome measures were change in weight, BMI SDS and percentage body weight. Secondary outcomes were side effects and cessation of treatment. RESULTS: After 6 months of treatment, statistically significant decreases in BMI SDS (0.32±0.27, p<0.001) and body weight (7.03±7.50 kg, p<0.001) were seen. Mean percentage total weight loss was 6.4±6.3% (p<0.001). For the 14 patients for whom 12-month data were available, statistically significant decreases were seen in mean BMI SDS (0.54±0.52, p<0.001). Mean body weight decreased by 9.7±10.8 kg (p<0.001). Percentage total weight loss at 12 months was 8.9±10.0% (p<0.001). Mild gastrointestinal side effects were common. One patient developed gallstones. Five patients discontinued treatment due to side effects. CONCLUSION: Semaglutide appears to be a safe and effective weight loss adjunct when used in a multidisciplinary weight management clinic.
引用
- van Boxel EJ, Rahman S, Lai K, et al. Semaglutide treatment for children with obesity: an observational study. Arch Dis Child. 2024. PMID: 38471743. doi:10.1136/archdischild-2023-326687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。